PDCD1 and neoplasm: Recent data focusing on lung cancer, colorectal cancer, or melanoma have suggested that the circulating mutation burden, identified by the massive parallel sequencing of cell-free DNA, may be correlated to the tumor mutation load and to the PD-1 and PD-L1 inhibitors’ efficacy [110,111,112].